<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3795">
  <stage>Registered</stage>
  <submitdate>6/02/2013</submitdate>
  <approvaldate>6/02/2013</approvaldate>
  <nctid>NCT01787747</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers</studytitle>
    <scientifictitle>A Phase 1, Single-center, Randomized, Double-blind, Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Doses of AVP-786 (Deuterated Dextromethorphan) in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>12-AVR-132</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AVP-786 Dose 1
Treatment: drugs - AVP-786 Dose 2
Treatment: drugs - AVP-786 Dose 1/Q Dose 1
Treatment: drugs - AVP-786 Dose 1/Q Dose 2
Treatment: drugs - AVP-786 Dose 2/Q Dose 2
Treatment: drugs - AVP-923

Experimental: Cohorts A and C - Single dose (D1) followed by twice daily dosing for 7 days

Experimental: Cohorts B and D - Single dose (D1) followed by twice daily dosing for 7 days

Experimental: Cohorts E and F - Single dose (D1) followed by twice daily dosing for 7 days

Experimental: Cohorts G and I - Single dose (D1) followed by twice daily dosing for 7 days

Experimental: Cohorts H and J - Single dose (D1) followed by twice daily dosing for 7 days


Treatment: drugs: AVP-786 Dose 1


Treatment: drugs: AVP-786 Dose 2


Treatment: drugs: AVP-786 Dose 1/Q Dose 1


Treatment: drugs: AVP-786 Dose 1/Q Dose 2


Treatment: drugs: AVP-786 Dose 2/Q Dose 2


Treatment: drugs: AVP-923


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma concentrations of parent and metabolites</outcome>
      <timepoint>8 Days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability - Assessments to include Physical Examination (PE), Labs, ECGs, and Adverse Events (AEs)</outcome>
      <timepoint>8 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy adult males

          -  18 - 45 years of age

          -  BMI 18 - 30 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History or presence of significant disease

          -  History of substance and/or alcohol abuse within the past 3 years

          -  Use of tobacco-containing or nicotine-contining products within 6 months

          -  Use of any prescription of over-the-counter (OTC) medication within 14 days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>48</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>CMAX - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Avanir Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess the single- and multiple-dose pharmacokinetic (PK), safety and tolerability of
      AVP-786 in healthy volunteers.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01787747</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sepehr Shakib, MD</name>
      <address>CMAX</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>